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Abstract
Objective To investigate the relation between cannabis use and
psychotic symptoms in individuals with above average
predisposition for psychosis who first used cannabis during
adolescence.
Design Analysis of prospective data from a population based
sample. Assessment of substance use, predisposition for
psychosis, and psychotic symptoms was based on standardised
personal interviews at baseline and at follow up four years later.
Participants 2437 young people (aged 14 to 24 years) with and
without predisposition for psychosis.
Main outcome measure Psychotic symptoms at follow up as a
function of cannabis use and predisposition for psychosis at
baseline.
Results After adjustment for age, sex, socioeconomic status,
urbanicity, childhood trauma, predisposition for psychosis at
baseline, and use of other drugs, tobacco, and alcohol, cannabis
use at baseline increased the cumulative incidence of psychotic
symptoms at follow up four years later (adjusted odds ratio
1.67, 95% confidence interval 1.13 to 2.46). The effect of
cannabis use was much stronger in those with any
predisposition for psychosis at baseline (23.8% adjusted
difference in risk, 95% confidence interval 7.9 to 39.7,
P = 0.003) than in those without (5.6%, 0.4 to 10.8, P = 0.033).
The risk difference in the “predisposition” group was
significantly greater than the risk difference in the “no
predisposition” group (test for interaction 18.2%, 1.6 to 34.8,
P = 0.032). There was a dose-response relation with increasing
frequency of cannabis use. Predisposition for psychosis at
baseline did not significantly predict cannabis use four years
later (adjusted odds ratio 1.42, 95% confidence interval 0.88 to
2.31).
Conclusion Cannabis use moderately increases the risk of
psychotic symptoms in young people but has a much stronger
effect in those with evidence of predisposition for psychosis.
Introduction
There is accumulating and converging evidence that cannabis
use may be a risk factor for psychotic symptoms.1 2 The possible
causal nature of the association between cannabis and psychosis,
however, is still a matter of debate, the main discussion revolving
around the role of predisposition for psychosis and adjustment
for confounders.3 4 According to the self medication hypothesis,5
individuals may start using cannabis because of predisposition
for psychosis, rather than cannabis use causing expression of
psychosis. To our knowledge, no prospective study to date has
tested this hypothesis using information on predisposition for
psychosis in relation to later cannabis use. Recent research, how-
ever, has suggested that rather than being the cause of cannabis
use, such predisposition interacts synergistically with cannabis
use. Two studies suggested that the joint effect of cannabis use
and predisposition for psychosis on the emergence of psychotic
symptoms was greater than the sum of their individual effects.2 6
We investigated prospectively whether cannabis use at
baseline increases the risk of subsequent development of
psychotic symptoms, whether any such increase in risk is higher
in individuals with a predisposition for psychosis, and whether
baseline expression predisposition increases the risk for
subsequent use of cannabis. We adjusted for possible confound-
ing factors in a large population-based sample of adolescents
and young adults.
Methods
Sample
The study was part of the early developmental stages of psycho-
pathology (EDSP) study,7 in which data were collected on the
prevalence, incidence, risk factors, comorbidity, and four year
course of mental disorders in a random regional representative
population sample of adolescents and young adults aged 14-24
years. The EDSP study is prospective, consisting of a baseline
survey in 1995, an assessment of a subsample in 1996-7, and a
four year follow up of the total sample in 1999.7 The current
analyses used the baseline and four year follow up data. The
study sample was randomly drawn from the respective
population registry offices of the city and each of the 29 counties
of Munich. The base population were all those born between 1
June 1970 and 31 May 1981 who were registered as living in
these areas as their primary place of residence and were German
citizens. At baseline 3021 participants were interviewed face to
face in their homes by using a computer assisted method
(response rate 71%). An average of 42 months after the baseline
investigations 2548 (response rate 84%) participants were
successfully followed up.Of these, 90 participants did not want to
respond to questions about illicit drug use at baseline or follow
up, and data on the psychosis section of the Munich version of
the international composite interview were incomplete for 21
participants. Our analyses were therefore of 2437 participants.
To have 80% power to detect an odds ratio of 2.5 at the 5% level,
given a base rate of psychotic experiences of 10% and a ratio of
unexposed to exposed of 6:1,2 8 we needed a sample size of 616.
As around four times as many subjects are required for an inter-
BMJ Online First bmj.com page 1 of 5
action such as between cannabis use and predisposition for psy-
chosis,9 the sample size of 2437 was large enough.
Instruments
Participants were interviewed by trained psychologists using the
Munich version of the composite international diagnostic inter-
view (M-CIDI).10 At baseline, they used the lifetime version of the
interview. The interval version was used at follow up, which refers
to the period of assessment between baseline and follow up. We
assessed data on the psychosis (G) section only at follow up and
these represent lifetime ratings. At baseline and at follow up, par-
ticipants additionally completed the self report symptom check-
list (SCL-90-R)11 to screen for a broad range of psychopathologi-
cal experiences including psychosis.
We used the “paranoid ideation” and “psychoticism”
subscales of the symptom checklist to explore predisposition for
psychosis at baseline and at follow up. Total scores of both
subscales were added into a total score. Participants with total
scores above the 90th centile were considered as having a
predisposition for psychosis, both at baseline and at follow up.
We defined an outcome of psychosis as at least one (broad
psychosis outcome) or at least two (narrow psychosis outcome)
positive ratings on any of the 15 core psychosis items of the
M-CIDI. We used the narrow outcome to exclude the possibility
of spurious results due to false positive misclassification. None of
these psychotic symptoms was due to acute effects of medication,
drugs, or alcohol.
To assess symptoms of depression at baseline and follow up
we calculated a mean score of the ratings on the 28 items of the
depression section (E) of the M-CIDI. We divided this into two
groups at the 90th centile, yielding a measure of significant
symptoms at both baseline and follow up.
We assessed use of cannabis and other substances using the
L-section of the M-CIDI. Individuals with lifetime cannabis use of
five times or more at baseline were considered as exposed to
cannabis. Cannabis exposure at baseline was defined as lifetime
cannabis use of five times or more (any use) and frequency of use
(use during the period of heaviest use: no use; less than once a
month; three to four times a month; once to twice a week; three
to four times a week; almost daily). Cannabis use at follow up was
analysed as cannabis use of five times or more during the four
years to follow up (any use at follow up). We combined psychos-
timulants, sedatives, opiates, cocaine, phencyclidine (PCP), and
psychedelic drugs into a group of “other drugs.” Lifetime
tobacco use at baseline was defined as daily use during at least
one month. Alcohol use at baseline was analysed as frequency of
use during the past 12 months (no use; less than once a month;
three to four times a month; once to twice a week; three to four
times a week; almost daily).
Statistical analyses
Associations between any use of cannabis or frequency of use at
baseline and psychotic symptoms at follow up were expressed as
odds ratios from logistic regression models in Stata, release 8.0
(StataCorp, College Station, TX). All analyses were a priori
adjusted for age, sex, socioeconomic status, urbanicity,12 and
experience of childhood trauma13 as well as for predisposition
for psychosis at baseline. To test whether the effect of cannabis
on psychosis was independent of other drugs, tobacco, alcohol,
and symptoms of depression at baseline and at follow up, we
entered these variables in the model with any cannabis use at
baseline. We also adjusted the effect of baseline cannabis on psy-
chotic symptoms according to the M-CIDI at follow up for pre-
disposition for psychosis at follow up.
The population attributable fraction was derived from the
associations between any use of cannabis and psychotic
symptoms according to the M-CIDI at follow up (adjusted for
demographics and trauma during childhood) in the logistic
regression models, both for the whole dataset and for the
individuals with expression of baseline predisposition, using the
aflogit procedure in Stata. This parameter gives a measure of the
proportion of cases in participants with psychotic symptoms
according to the M-CIDI at follow up that could have been pre-
vented, assuming causality, had the exposure to cannabis been
eliminated completely from the baseline population.
We calculated the interaction between predisposition for psy-
chosis at baseline and any cannabis use (adjusted for
demographics, childhood trauma, and predisposition at follow
up) under an additive model rather than a multiplicative model
because an additive model is more likely to yield information on
the degree of synergism between causes—that is, the extent to
which both causes depend on each other or coparticipate in dis-
ease causation.14 15
We investigated the self medication hypothesis by calculating
the association between predisposition for psychosis at baseline
and cannabis use at follow up, both for the whole dataset and for
the individuals who had not used cannabis at baseline. We used
sensitivity analyses to examine whether differential attrition in
the sample as a whole (3021 at baseline, 2437 at follow up) could
have biased the findings. This was done by multiple imputation
of missing values of cannabis use at baseline, predisposition for
psychosis at baseline, and psychotic symptoms according to the
M-CIDI at follow up with the hotdeck command in Stata.
Results
We followed up 2437 participants, of which 1251 (51.3%) were
men. The mean age was 18.3 years (SD 3.3 years) at baseline and
21.8 years (3.4 years) at follow up. At four year follow up the
cumulative lifetime incidence of at least one psychotic symptom
was 424 (17.4%), irrespective of severity and impairment probe
criteria, and 174 (7.1%) participants reported two or more
psychotic symptoms. At baseline 320 (13.1%) admitted to any use
of cannabis (five times or more) and 361 (14.8 %) did so at follow
up.
Any cannabis use at baseline increased the risk of psychotic
symptoms according to the M-CIDI at follow up four years later
in a dose-response fashion (tables 1-3), regardless of confound-
ers, and with larger effect sizes for the narrowly defined psycho-
sis outcome.
The effect of baseline cannabis use on the psychosis outcome
according to the M-CIDI at follow up four years later was much
stronger in those with predisposition for psychosis at baseline
(23.8% adjusted difference in risk) than in those without (5.6%
adjusted difference in risk, table 4). The population attributable
fraction was 6.2% for the total group and more than twice as
large (14.2%) for the group with predisposition for psychosis at
baseline.
Predisposition for psychosis at baseline did not significantly
predict cannabis use at follow up four years later (odds ratio 1.42,
95% confidence interval 0.94 to 2.15, for the whole sample and
1.42, 0.88 to 2.31, for the subgroup with no cannabis use at base-
line).
Based on 1000 imputation sequences in which we stochasti-
cally imputed missing values of cannabis use at baseline and psy-
chotic symptoms according to the M-CIDI at four year follow up
in the whole sample, the estimated average additive interaction
between predisposition for psychosis at baseline and cannabis
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use at baseline remained significant (19.5% difference in risk,
95% confidence interval 0.3 to 38.6, P = 0.039).
Discussion
Exposure to cannabis during adolescence and young adulthood
increases the risk of psychotic symptoms later in life. The
findings confirm earlier suggestions that this association is
stronger for individuals with predisposition for psychosis2 6 and
stronger for the more severe psychotic outcomes.2 6 Frequent use
of cannabis was associated with higher levels of risk in a
dose-response fashion. Associations were independent of other
variables known to increase the risk for psychosis. Also, the effect
of cannabis remained significant after we corrected for baseline
use of other drugs, tobacco, and alcohol. Finally, the data did not
support the self medication hypothesis as baseline predisposi-
tion for psychosis did not significantly predict cannabis use at
follow up.
Strengths and weaknesses
We examined psychotic symptoms according to the M-CIDI at
follow up in a non-clinical sample. Symptoms were more preva-
lent than psychotic disorders defined according to the Diagnostic
and Statistic Manual of Mental Disorders, fourth edition, but never-
theless have been shown to be on the same continuum of expe-
riences as more severe states of psychosis, such as schizophre-
nia.8 16 Established risk factors for schizophrenia, such as
urbanicity and familial predisposition, also affect the occurrence
of psychotic symptoms.15 17 Our results confirm those from three
previous studies that showed that exposure to cannabis plays a
part not only in the expression of psychotic disorder but also in
the emergence of less severe psychotic experiences.2 6 18
At baseline we used self reported psychotic experiences on
the symptom checklist to determine predisposition for
psychosis, whereas at follow up four years later we used the
M-CIDI to determine psychosis outcome. In the group with pre-
disposition for psychosis at baseline, any effect of cannabis can
thus be interpreted as psychosis persisting from baseline to
follow up (if we assume that the two measures of psychosis are
identical), rather than an effect of transition from expression of
predisposition at baseline to expression of overt symptoms at
follow up. Although both explanations would be equally impor-
tant, adjustment for the effect of the follow up equivalent of the
baseline measure of predisposition for psychosis did not change
the observed association between cannabis and psychotic symp-
toms according to the M-CIDI, indicating that the effect of can-
nabis can be interpreted as onset of clinical psychosis outside the
continuity between the measure of predisposition for psychosis
at baseline and follow up. In addition, cannabis also had a signifi-
cant effect on psychotic symptoms in the group without predis-
position for psychosis at baseline, albeit of smaller effect.
Synergistic interaction between cannabis and predisposition
for psychosis
Findings from earlier research suggest biological plausibility,
involving the endocannabinoid CB1 receptor system in close
interaction with the dopamine neurotransmitter system. For
example, delta-9-tetrahydrocannabinol (the major psychoactive
component of cannabis) increases presynaptic dopamine efflux
and utilisation in the prefrontal cortex in rats.19 Increased
concentrations of CB1 receptors were found in the dorsolateral
prefrontal cortex of patients with schizophrenia,20 and concen-
trations of anandamide (an endogenous cannabinoid that binds
to the CB1 receptor) were found to be higher in the cerebrospi-
nal fluid of these patients.21 Furthermore, there is evidence from
animal studies that puberty in rats is a vulnerable period with
respect to the adverse effects of cannabinoids.22 The longlasting
behavioural disturbances observed in this animal study are con-
sistent with impairments generally found in patients with schizo-
phrenia, and the changes in these rats were reversed by the acute
administration of the dopamine antagonist haloperidol.22
Repeated exposure to cannabis may cause initial increases in
synaptic dopamine and then lead to more prolonged changes in
the endogenous cannabinoid systems. These changes might be
most profound after exposure to cannabis during adolescence
and in individuals with a pre-existing vulnerability to dysregula-
tion of the cannabinoid system and related neurotransmission
systems.
This work is part of the early developmental stages of psychopathology
(EDSP) study. Principal investigators are Hans-Ulrich Wittchen and
Roselind Lieb. Current or former staff members of the EDSP group include
Kirsten von Sydow, Gabriele Lachner, Axel Perkonigg, Peter Schuster,
Michael Höfler, Holger Sonntag, Esther Beloch, Martina Fuetsch, Elzbieta
Garczynski, Alexandra Holly, Barbara Isensee, Chris Nelson, Hildegard
Table 1 Patterns of cannabis use at baseline and psychotic symptoms at follow up. Figures are numbers (percentages) of participants
Cannabis use at baseline
Any psychotic symptom at follow up At least two psychotic symptoms at follow up
Yes (n=424) No (n=2013) Yes (n=174) No (n=2263)
Any use (≥5 times) 82 (19.3) 238 (11.8) 44 (25.3) 276 (12.2)
Cumulative frequency*:
None 342 (80.7) 1775 (88.2) 130 (74.7) 1987 (87.8)
<1 times/month 13 (3.1) 69 (3.4) 5 (2.9) 77 (3.4)
3-4 times/month 18 (4.2) 62 (3.1) 10 (5.7) 70 (3.1)
1-2 times/week 17 (4.0) 40 (2.0) 7 (4.0) 50 (2.2)
3-4 times/week 12 (2.8) 21 (1.0) 8 (4.6) 25 (1.1)
Almost daily 22 (5.2) 46 (2.3) 14 (8.0) 54 (2.4)
*Some percentages do not total 100 because of rounding.
Table 2 Associations between any cannabis use at baseline and psychotic symptoms at follow up. Figures are odds ratios (95% confidence intervals)
Cannabis exposure at
baseline
Any psychotic symptom
At least two psychotic
symptoms
Unadjusted Adjusted* Additional adjustment† Additional adjustment‡ Adjusted*
Any use (≥5 times) 1.79 (1.36 to 2.36) 1.69 (1.26 to 2.25) 1.67 (1.13 to 2.46) 1.53 (1.13 to 2.07) 2.23 (1.52 to 3.29)
*Age, sex, socioeconomic status, urbanicity, childhood trauma, and predisposition for psychosis at baseline.
†Also adjusted for other drug use, tobacco, and alcohol.
‡Also adjusted for predisposition for psychosis at follow up and depression at baseline and follow up.
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Table 3 Associations between frequency of cannabis use at baseline and
any psychotic symptoms. Figures are odds ratios (95% confidence intervals)
Cumulative frequency of
cannabis use Unadjusted Adjusted*
None† 1 1
<1/month 1.01 (0.55 to 1.86) 0.99 (0.53 to 1.84)
3-4 times/month 1.56 (0.91 to 2.68) 1.50 (0.86 to 2.62)
1-2 times/week 2.28 (1.28 to 4.09) 1.95 (1.07 to 3.55)
3-4 times/week 3.07 (1.49 to 6.31) 2.44 (1.16 to 5.13)
Almost daily 2.57 (1.52 to 4.34) 2.23 (1.30 to 3.84)
Linear trend‡ 1.24 (1.15 to 1.35) 1.20 (1.10 to 1.31)
*Adjusted for age, sex, socioeconomic, urbanicity, childhood trauma, and predisposition for
psychosis at baseline.
†Reference category.
‡Increase in risk with one unit change in cannabis frequency.
Table 4 Interactions between any cannabis use and predisposition for psychosis
Cannabis use at baseline
No with psychosis
outcome*
No without psychosis
outcome*
Risk of psychotic symptoms at
follow up
Difference in risk
Unadjusted Adjusted† (95% CI)
No predisposition for psychosis at baseline
None 294 1642 15% 6% 5.6% (0.4 to 10.8) P=0.033
Any (≥5 times) 59 216 21%
Predisposition for psychosis at baseline‡
None 47 133 26% 25% 23.8% (7.9 to 39.7) P=0.003
Any (≥5 times) 23 22 51%
*Numbers total 2436 because of one missing value on predisposition for psychosis at baseline.
†Age, sex, socioeconomic status, urbanicity, childhood trauma, and predisposition for psychosis at follow up. Test for additive interaction 18.2% adjusted difference in risk (95% confidence
interval 1.6 to 34.8), P=0.032 (tests whether risk difference in “predisposition” group is significantly greater than risk difference in “no predisposition” group).
‡Total score ≥90th centile on “paranoid ideation” and “psychoticism” subscales of symptom checklist.
What is already known on this topic
It is generally accepted that cannabis use is strongly
associated with psychosis
We do not know whether the association is causal or
whether those with a predisposition for psychosis are
particularly at risk
What this study adds
Cannabis use in young people moderately increased the
risk of developing psychotic symptoms
The risk for the onset of symptoms was much higher in
young people with a predisposition for psychosis
Predisposition psychosis at baseline did not predict
cannabis use at follow up, thus refuting the self medication
hypothesis
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